Short Interest in Virax Biolabs Group Limited (NASDAQ:VRAX) Expands By 205.8%

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a large increase in short interest in February. As of February 15th, there was short interest totalling 180,400 shares, an increase of 205.8% from the January 31st total of 59,000 shares. Approximately 4.5% of the shares of the stock are short sold. Based on an average trading volume of 367,600 shares, the short-interest ratio is presently 0.5 days.

Virax Biolabs Group Stock Down 1.2 %

NASDAQ:VRAX opened at $1.71 on Friday. The business’s 50-day moving average price is $2.01 and its two-hundred day moving average price is $2.29. Virax Biolabs Group has a twelve month low of $0.60 and a twelve month high of $9.00.

Institutional Trading of Virax Biolabs Group

A hedge fund recently bought a new stake in Virax Biolabs Group stock. XTX Topco Ltd acquired a new stake in shares of Virax Biolabs Group Limited (NASDAQ:VRAX) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 11,863 shares of the company’s stock, valued at approximately $27,000. XTX Topco Ltd owned about 0.37% of Virax Biolabs Group at the end of the most recent quarter. Institutional investors and hedge funds own 8.61% of the company’s stock.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.